Patents by Inventor Sara D'Angelo

Sara D'Angelo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY AFFINITY MATURATION USING NATURAL LIABILITY-FREE CDRS
    Publication number: 20230167165
    Abstract: Provided herein is an improved method of antibody affinity maturation that uses true natural CDRs from a population of naturally occurring antibodies targeting a single antigen or antigenic epitope such that the improved method produces functional antibodies having low-picomolar affinity antibodies. Also provided herein is an antibody library where the CDRs within a single antibody member of the library are a combination of CDR sequences of naturally occurring antibodies and one or more CDRs are derived from different naturally occurring antibodies targeting a single antigen or antigenic epitope.
    Type: Application
    Filed: July 7, 2022
    Publication date: June 1, 2023
    Inventors: Andrew Raymon Morton Bradbury, Sara D'Angelo, Andre A. Teixeira
  • Phage-Displayed Accessible Recombinant Targeted Antibodies and Methods of Making Same
    Publication number: 20230139913
    Abstract: Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.
    Type: Application
    Filed: October 18, 2022
    Publication date: May 4, 2023
    Inventors: Renata Pasqualini, Wadih Arap, Fernanda Iamassaki Staquicini, Fortunato Ferrara, Sara D'Angelo, Andrew R.M. Bradbury
  • GRP78-BINDING ANTIBODIES AND USES THEREOF AND SELECTION OF PHAGE-DISPLAYED ACCESSIBLE RECOMBINANT TARGETED ANTIBODIES
    Publication number: 20230028927
    Abstract: Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.
    Type: Application
    Filed: June 10, 2022
    Publication date: January 26, 2023
    Inventors: Renata Pasqualini, Wadih Arap, Fernanda Iamassaki Staquicini, Fortunato Ferrara, Sara D'Angelo, Andrew R.M. Bradbury
  • GRP78-BINDING ANTIBODIES AND USES THEREOF AND SELECTION OF PHAGE-DISPLAYED ACCESSIBLE RECOMBINANT TARGETED ANTIBODIES
    Publication number: 20220348680
    Abstract: Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.
    Type: Application
    Filed: June 10, 2022
    Publication date: November 3, 2022
    Inventors: Renata Pasqualini, Wadih Arap, Fernanda Iamassaki Staquicini, Fortunato Ferrara, Sara D'Angelo, Andrew R.M. Bradbury
  • GRP78-BINDING ANTIBODIES AND USES THEREOF AND SELECTION OF PHAGE-DISPLAYED ACCESSIBLE RECOMBINANT TARGETED ANTIBODIES
    Publication number: 20220306763
    Abstract: Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.
    Type: Application
    Filed: February 4, 2022
    Publication date: September 29, 2022
    Inventors: Renata Pasqualini, Wadih Arap, Fernanda Iamassaki Staquicini, Fortunato Ferrara, Sara D'Angelo, Andrew R.M. Bradbury
  • EphA5-binding antibodies and uses thereof and selection of phage-displayed accessible recombinant targeted antibodies
    Patent number: 11254751
    Abstract: Isolated or recombinant Eph A5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: February 22, 2022
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Renata Pasqualini, Wadih Arap, Fernanda Iamassaki Staquicini, Fortunato Ferrara, Sara D'Angelo, Andrew R. M. Bradbury